HDAC Inhibitors-New Generation of Target Specific Treatment

Title: HDAC Inhibitors-New Generation of Target Specific Treatment

Volume: 10 Issue: 13

Author(s): A. V. Chavan and R. R. Somani

Affiliation:

Keywords: Histone Deacetylase, HDAC inhibitor, chemistry, therapeutic applications, Enzyme Histone acetyltransferases, HAT, Class III HDACs, sirtuins, nu-clear receptor co-repressor, N-coR, Silencing Mediator, Thyroid receptors, SMRT, HDAC enzyme, aliphatic chain, Large hydrophobic region, Hydroxamic acids, trichostatin, TSA, suberoylanilide hydroxamic acid, SAHA, oxamflatin, Cyclic tetrapeptides, Benzamides, MS-27-275, Short-chain fatty acids, butyrates, Streptomyces hygro-scopicus, NVP-LAQ824, LAQ824, PDX 101, LDH589, Depsipeptide FK228, Chromobacterium violaceum, Apicidin, tubacin, Vorinostat, suberoylanilide hy-droxamic acid, Valproic acid, VPA, Trichostatin A

Abstract: Histone Deacetylases (HDACs) enzymes are critical in regulating gene expression and transcription. They also play a fundamental role in regulating cellular activities such as cell proliferation, survival and differentiation. Inhibition of HDACs has generated many fascinating results including a new strategy in human cancer therapy. HDAC Inhibitors (HDACIs) like SAHA, TSA are emerging as new promising drugs for various anti-inflammatory and CNS-disorders. This review, along with chemical classification, emphasizes on the therapeutic potential of various HDACIs against different diseases.

Cite this article as:

V. Chavan A. and R. Somani R., HDAC Inhibitors-New Generation of Target Specific Treatment, Mini-Reviews in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/13895575110091263